Information Provided By:
Fly News Breaks for September 28, 2015
CEMP
Sep 28, 2015 | 09:11 EDT
Roth Capital notes that Cempra's stock has fallen 13% over the past five days. The firm blames the decline on worries about the sustainability of drug prices. However, Roth says that Cempra's solithromycin antibiotic could cost under $1,000 for the full IV-course, making it competitive against generics. If solithromycin proves to be superior to IV moxifloxacin,, a $1,000+ price range for solithromycin "might be a compelling proposition for payers and hospitals," and the drug could easily generate multi-billion dollars of revenue, according to Roth. The firm keeps a Buy rating on the shares.
News For CEMP From the Last 2 Days
There are no results for your query CEMP